An update on the pharmacology of galantamine
- 28 November 2007
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 16 (12) , 1987-1998
- https://doi.org/10.1517/13543784.16.12.1987
Abstract
(2007). An update on the pharmacology of galantamine. Expert Opinion on Investigational Drugs: Vol. 16, No. 12, pp. 1987-1998. doi: 10.1517/13543784.16.12.1987Keywords
This publication has 86 references indexed in Scilit:
- Stimulation of nicotinic acetylcholine receptors protects motor neuronsBiochemical and Biophysical Research Communications, 2005
- Galantamine modulates nicotinic receptor and blocks Aβ-enhanced glutamate toxicityBiochemical and Biophysical Research Communications, 2004
- Galantamine and memantine produce different degrees of neuroprotection in rat hippocampal slices subjected to oxygen–glucose deprivationNeuroscience Letters, 2004
- Turning down, but not offNature, 2004
- A multinational, randomised, 12‐week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's diseaseInternational Journal of Geriatric Psychiatry, 2004
- Galantamine Provides Sustained Benefits in Patients with ‘Advanced Moderate’ Alzheimer’s Disease for at Least 12 MonthsDementia and Geriatric Cognitive Disorders, 2003
- Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefitJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 2002
- Clinical Pharmacokinetics and Pharmacodynamics of Cholinesterase InhibitorsClinical Pharmacokinetics, 2002
- Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivoLife Sciences, 1990
- Oral Tetrahydroaminoacridine in Long-Term Treatment of Senile Dementia, Alzheimer TypeNew England Journal of Medicine, 1986